These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 31727211)

  • 1. The psychopharmacology of Huntington disease.
    Petersén Å; Weydt P
    Handb Clin Neurol; 2019; 165():179-189. PubMed ID: 31727211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deutetrabenazine for the treatment of Huntington's chorea.
    Bashir H; Jankovic J
    Expert Rev Neurother; 2018 Aug; 18(8):625-631. PubMed ID: 29996061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of deutetrabenazine: a novel treatment for chorea associated with Huntington's disease.
    Dean M; Sung VW
    Drug Des Devel Ther; 2018; 12():313-319. PubMed ID: 29497277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene therapy offers HD patients relief from some symptoms. Tetrabenazine inhibits the transport of a molecule called vesicular monoamine transporter type 2 or VMAT2.
    Morrow T
    Manag Care; 2008 Nov; 17(11):46-7. PubMed ID: 19052001
    [No Abstract]   [Full Text] [Related]  

  • 5. Deutetrabenazine: A Review in Chorea Associated with Huntington's Disease.
    Heo YA; Scott LJ
    Drugs; 2017 Nov; 77(17):1857-1864. PubMed ID: 29080203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deutetrabenazine (Austedo) for Huntington's chorea and tardive dyskinesia.
    Med Lett Drugs Ther; 2018 Apr; 60(1545):65-68. PubMed ID: 29667946
    [No Abstract]   [Full Text] [Related]  

  • 7. Tetrabenazine (Xenazine) for Huntington's chorea.
    Med Lett Drugs Ther; 2009 Jan; 51(1304):7-8. PubMed ID: 19172140
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparing pharmacologic mechanism of action for the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine in treating tardive dyskinesia: does one have advantages over the other?
    Stahl SM
    CNS Spectr; 2018 Aug; 23(4):239-247. PubMed ID: 30160230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Profiling deutetrabenazine extended-release tablets for tardive dyskinesia and chorea associated with Huntington's disease.
    Moondra P; Jimenez-Shahed J
    Expert Rev Neurother; 2024 Sep; 24(9):849-863. PubMed ID: 38982802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tetrabenazine Treatment Patterns and Outcomes for Chorea Associated with Huntington Disease: A Retrospective Chart Review.
    Claassen DO; Iyer RG; Shah-Manek B; DiBonaventura M; Abler V; Sung VW
    J Huntingtons Dis; 2018; 7(4):345-353. PubMed ID: 30282372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deutetrabenazine for tardive dyskinesia and chorea associated with Huntington's disease: a review of clinical trial data.
    Claassen DO; Philbin M; Carroll B
    Expert Opin Pharmacother; 2019 Dec; 20(18):2209-2221. PubMed ID: 31613641
    [No Abstract]   [Full Text] [Related]  

  • 12. Deutetrabenazine in the treatment of Huntington's disease.
    Richard A; Frank S
    Neurodegener Dis Manag; 2019 Feb; 9(1):31-37. PubMed ID: 30624137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders.
    Guay DR
    Am J Geriatr Pharmacother; 2010 Aug; 8(4):331-73. PubMed ID: 20869622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VMAT2 Inhibitors for Tardive Dyskinesia-Practice Implications.
    Peckham AM; Nicewonder JA
    J Pharm Pract; 2019 Aug; 32(4):450-457. PubMed ID: 29455579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tetrabenazine: for chorea associated with Huntington's disease.
    Scott LJ
    CNS Drugs; 2011 Dec; 25(12):1073-85. PubMed ID: 22133328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Experience With Deutetrabenazine for Huntington Disease Chorea.
    Curtis K; Sung V
    J Clin Pharmacol; 2024 Feb; 64(2):178-181. PubMed ID: 37565322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tetrabenazine in the treatment of hyperkinetic movement disorders.
    Kenney C; Jankovic J
    Expert Rev Neurother; 2006 Jan; 6(1):7-17. PubMed ID: 16466307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of Chorea.
    Frank S; Stamler D; Kayson E; Claassen DO; Colcher A; Davis C; Duker A; Eberly S; Elmer L; Furr-Stimming E; Gudesblatt M; Hunter C; Jankovic J; Kostyk SK; Kumar R; Loy C; Mallonee W; Oakes D; Scott BL; Sung V; Goldstein J; Vaughan C; Testa CM;
    JAMA Neurol; 2017 Aug; 74(8):977-982. PubMed ID: 28692723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Huntington's disease.
    Frank S
    Neurotherapeutics; 2014 Jan; 11(1):153-60. PubMed ID: 24366610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deutetrabenazine: Treatment of hyperkinetic aspects of Huntington's disease, tardive dyskinesia and Tourette syndrome.
    Paton DM
    Drugs Today (Barc); 2017 Feb; 53(2):89-102. PubMed ID: 28387387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.